Table 3.
| Study arms | Number of patients in each group | Age (years) | ||||||
|---|---|---|---|---|---|---|---|---|
| ID | Intervention (the name and the form of the durg) | Control (placeob or another durg) | Intervention | Control | Intervention | Control | Cardiovascular risk | Blood pressure (mmHg) |
| TIPS 3 - (16) | 1- Polycap (thiazide 25 mg, atenolol 100 mg, ramipril 10 mg, simvastatin 40 mg) taken once daily 2- Aspirin 75 mg daily 3- Vitamin D 60,000 IU monthly | Matching placebo | 5,713 | 63.9 (6.6) | — | SBP: 144.5 (16.8) DBP: 83.9 (9.7) |
||
| HOPE 3 | 1- polypill (Candesartan 16 mg/HCT 12.5 mg) 2- Rosuvastatin 10 mg | Placebo | (Candesartan /HCTZ) Asian: 3,118 non-asians: 3,238 |
Asian: 3123 non-asians: 3,226 | Asian: 64.75 (5.99) non-asians: 66.40 (6.62) | Asian: 64.88 (6.02) non-asians: 66.41 (6.58) | Framingham risk score, N (%): (polypill) Asian: 23.28 (13.41) non asian: 21.37 (11.99) (placebo) asian: 22.68 (13.31) non-asians: 21.22 (11.96) | (polypill) Asian: 139.86 (14.15)/82.55 (9.14) Non-Asian: 136.61 (15.16) / 81.38 (9.58) (placebo) Asian: 139.82 (14.44) / 82.31 (9.00) Non-Asians: 135.96 (14.9) / 81.21 (9.45) |
| Polyiran | 1- polypill 1, (hydrochloro thiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg and enalapril 5 mg.) 2- (those who develop cough at follow up): polypill 2, (valsartan 40 mg instead of enalapril 5 mg) |
Minimal care | 3,421 | 3,417 | mean (95%CI) 59.3 (59.0–59.6) | 59.7 (59.4–60.1) | — | polypill: SBP: 130.2 DBP: 78.5 minimal care: SBP: 131.9 DBP: 79.2 |
| HOPE 4 | Polypill: combination of two antihypertensives included an angiotensin receptor blocker or angiotensin converting enzyme inhibitor coupled with a diuretic or calcium channel blocker, with atorvastatin at 20 mg or rosuvastatin at 10 mg | Usual care | 644 | 727 | 65.1 (9.1) | 65.8 (9.7) | Control: 35.5% (22.3) Intervention: 32.6% (21.4) | Control: SBP: 151.7 (15.6) DBP: 85.3 (11.9) intervention: SBP: 152.1 (15.4) DBP: 84.7 (12.0) |
| SCCS | (polypill) once daily containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg. | Usual care | 148 | 155 | 56 (6) | 56 (6) | Control: 13.0 ± 10.1 Intervention: 12.4 ± 8.9 | SBP: control: 140 (17) intervention: 140 (18) |
| Soliman et al. (21) | The polypill (Red Heart pill 2b): -aspirin (75 mg), -simvastatin (20 g), -lisinopril (10 mg) and -hydrochlorothiazide (12.5 mg) | Standard practice (management of their CVD risk according to the usual care given to participants in similar conditions) | 105 | 111 | 59.0 ± 6.9 | 59.2 ± 7.4 | Polypill: 44.1 ± 20.3 standard practice: 41.6 ± 19.8 | SBP: 165.2 ± 18.2 |
| Malekzadeh | Polypill: • Aspirin (81 mg) • Enalapril (2.5 mg) • Etorvastatin (20 mg) • Hydrochlorothiazide (12.5 mg) | Placebo | 241 | 234 | 59.0 ± 6.5 | 59.1 ± 7.3 | — | Polypill: SBP: 124.8 ± 17.3 DBP: 78.4 ± 10.4 placebo: SBP: 130.3 ± 17.4 DBP: 81.2 ± 9.7 |
| OLSTA | 1- FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin) 2- 40 mg olmesartan medoxomil 3- 20 mg rosuvastatin |
Placebo | 1-FDC therapy group = 61 2-Olmesartan medoxomil group = 36 3-Rosuvastatin group = 36 |
29 | 1-FDC therapy group = 61.9 (8.1) 2-Olmesartan medoxomil group = 59.5 (6.9) 3-Rosuvastatin group = 61.8 (8.0) |
62.5 (8.2) | -Intervention: 1-FDC therapy group = SBP: 150.6 (11.9) DBP: 92.0 (7.4) 2-Olmesartan medoxomil group = SBP: 150.6 (15.5) DBP: 93.3 (5.0) 3-Rosuvastatin group = SBP: 148.9 (13.3) DBP: 92.9 (6.5) -Control: SBP: 152.2 (14.5) DBP: 92.5 (7.0) |
|